Parkinson’s Disease – China In Depth – Parkinson’s Disease – China In-Depth (China)
Parkinson’s disease is a chronic neurodegenerative disease characterized by progressively worsening motor symptoms. Treatment of Parkinson’s disease in China comprises a broad range of symptomatic therapies including, dopamine precursors, dopamine agonists, MAO-B inhibitors, and COMT inhibitors. The expected imminent approval of safinamide—the third-to-market MAO-B inhibitor—and LY03003—the reformulation of rotigotine, a dopamine agonist, that offers a more convenient once-weekly dosing advantage—have the potential to meaningfully change the treatment paradigm of Parkinson’s disease in China. The uptake of these therapies, in addition to the growing aging-led prevalence of the disease in the country, will lead to significant growth of the Parkinson’s disease market of China during the 2021-2031 period. Additionally, in view of the ongoing reforms in China’s regulatory and access and reimbursement landscape, multinational companies will be increasingly encouraged to enter this market.
Questions answered
- How large is China’s drug-treatable Parkinson’s disease population, and how will the drug-treatment rate change during the forecast period?
- What are the most commercially relevant drugs in China’s Parkinson’s disease market, and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
- What are the key market access considerations for key therapies in the Parkinson’s disease pipeline of China? What sales / uptake could they secure in Parkinson’s disease?
- What are the key drivers and constraints in the Chinese Parkinson’s disease market, and how will the market evolve over the forecast period?
Content highlights
Geography: China
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 neurologists
Epidemiology: Diagnosed prevalence of Parkinson’s disease in urban versus rural China; clinically relevant and market-relevant drug-treatable populations
Forecast: 10-year, annualized, drug-level sales and patient shares of key heart failure therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions
Product Description
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Table of contents
Samantha Wang, Healthcare Research & Data Analyst, China In-Depth. With an educational background in business management, Ms. Wang has experience researching the regulatory reforms in China pertaining to drug and medical device registration and market access. She is now involved in drafting disease landscape reports focusing on the treatment of various indications in China, such as gastroesophageal cancer, Alzheimer’s disease, rheumatoid arthritis, and heart failure. She also provides the team with local language and cultural support, as well as participates in interviewing physicians in China and answering client queries.